Latest Whitepapers

As we have gained a greater understanding of cancer biology, therapeutic interventions have evolved from a one-size-fits-all approach to more targeted approaches, which afford patients not only longer lives but increased quality of life.

At high levels, host cell proteins (HCPs) can cause immunogenic responses and reduced efficacy of biologics, so it is imperative to have an effective, robust HCP assay to detect them and mitigate these effects.

Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. However, not all patients respond to immunotherapy.

Novel and emerging infectious diseases can be a serious threat to human health and the global economy, as exhibited by the current SARS-CoV-2 outbreak. To mitigate these threats, it is necessary to initiate comprehensive containment strategies such as

Download this whitepaper to learn about the advantages of calibration certificates, concepts of accredited calibration and traceability of test equipment.

While common laboratory plastics are generally regarded as inert by researchers, some commonly used products such as pipette tips and sample tubes have been reported to leach chemical compounds including oleamide, erucamide and DiHEMDA.

Download this whitepaper to discover how next-generation ELISA technology can accelerate biomarker discovery and provide in-depth analysis of COVID-19 host cytokine levels.

Download this whitepaper to learn more about how dilutional linearity enhances reliability, undetected HCP can be minimized as well as consistently low variation ensures reproducible data.

Proteins are one of the most vital parts of living organisms with many functions, using the latest proteomics methods it is now possible to understand how protein changes in our body influence health and disease, particularly during ageing.

The rapid and cost-effective production of conventional monoclonal antibodies (mAbs) for clinical trials has contributed toward their wide adoption. As the number of next-generation antibody-based candidates with modified or absent Fc domains increases, biomanufacturers face a need to establish alternative affinity purification technologies.